TScan Therapeutics, Inc.
TCRX Healthcare Biotechnology
TScan Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.3 million, up 266.7% from fiscal 2024. In the quarter to June 2026, revenue fell 65.8%, EPS grew 17.9%, free cash flow grew 19.0% and total debt rose 1.50%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TCRX
TScan Therapeutics, Inc. (TCRX) EV/Sales
As of 16 October 2026, TScan Therapeutics, Inc. (TCRX) trades at a EV/Sales of −5.3×. Over the past ten years it has ranged from −34.3× (March 2025) to 52.0× (May 2024); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (94.05%) |
| FY2024 | 32.9× | 226.12% |
| FY2023 | 10.1× | — |
| FY2022 | −3.4× | — |
| FY2021 | −10.1× | — |
| FY2020 | −14.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.4× | 66.98% |
| Mar 2026 | 5.1× | 157.65% |
| Dec 2025 | 2.0× | (82.54%) |
| Sep 2025 | 11.2× | 515.80% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| TCRX TScan Therapeutics, Inc. | −5.3× |
| AKTX Akari Therapeutics PLC compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.9× |
| DYAI Dyadic International Inc. compare | 4.0× |
| ACGN Aceragen, Inc. compare | 4.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)